Is that an­oth­er IPO in the mak­ing? Ex-No­var­tis CEO Joe Jimenez and a lead Kite play­er take up new posts at an off-the-shelf ri­val to 2 pi­o­neer­ing drugs

Right on the heels of tak­ing on a $160 mil­lion crossover round in a like­ly leap to Nas­daq, Cen­tu­ry Ther­a­peu­tics CEO La­lo Flo­res is now push­ing ahead with the high-pro­file ex-No­var­tis chief Joe Jimenez as chair­man.

Jimenez’s great­est fame at No­var­tis was earned for one of its weak­est prod­ucts, as their pi­o­neer­ing per­son­al­ized CAR-T Kym­ri­ah won the hon­ors for the first such drug to make it to the mar­ket. Now a host of play­ers, in­clud­ing Cen­tu­ry, are bar­rel­ing in be­hind the fron­trun­ners with al­lo­gene­ic ri­vals that can be cre­at­ed for off-the-shelf use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER